Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

被引:0
作者
Xin-Lin Zhang
Qing-Qing Zhu
Li Zhu
Jian-Zhou Chen
Qin-Hua Chen
Guan-Nan Li
Jun Xie
Li-Na Kang
Biao Xu
机构
[1] Nanjing University School of Medicine,Department of Cardiology, Affiliated Drum Tower Hospital
[2] Jinling Hospital,Department of Respiratory Medicine
[3] Nanjing University School of Medicine,Department of Radiology, Affiliated Drum Tower Hospital
[4] Nanjing University School of Medicine,undefined
来源
BMC Medicine | / 13卷
关键词
PCSK9; Monoclonal antibody; Evolocumab; Alirocumab; Safety; Efficacy; LDL-C; Meta-analysis; Randomized controlled trials;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 215 条
[1]  
Stone NJ(2001)Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 285 2486-97
[2]  
Robinson JG(2014)2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2889-934
[3]  
Lichtenstein AH(2014)Lipid lowering with PCSK9 inhibitors Nat Rev Cardiol 11 563-75
[4]  
Bairey MC(2003)Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 154-6
[5]  
Blum CB(2007)Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 282 18602-12
[6]  
Eckel RH(2015)Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia Am J Cardiol 115 1212-21
[7]  
Dadu RT(2014)Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 1870-82
[8]  
Ballantyne CM(2014)Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 60-8
[9]  
Abifadel M(2008)Combination of simvastatin with berberine improves the lipid-lowering efficacy Metabolism 57 1029-37
[10]  
Varret M(2008)A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease J Am Coll Cardiol 52 894-904